Nephros Stock Performance
| NEPH Stock | USD 1.61 0.02 1.23% |
On a scale of 0 to 100, Nephros holds a performance score of 4. The company secures a Beta (Market Risk) of 0.52, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nephros' returns are expected to increase less than the market. However, during the bear market, the loss of holding Nephros is expected to be smaller as well. Please check Nephros' semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Nephros' current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nephros are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent basic indicators, Nephros demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:9 | Dividend Date 2019-07-10 | Last Split Date 2019-07-10 |
1 | Acquisition by Amron Arthur H of 4582 shares of Nephros subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Spandow Oliver J. of 7050 shares of Nephros at 1.47 subject to Rule 16b-3 | 12/31/2024 |
3 | AtriCure Stock Surges Over 5 percent Amid Market Activity - GuruFocus.com | 01/15/2025 |
4 | Insider Buyers Lose US47k As Nephros Sheds US2.0m | 02/06/2025 |
5 | Acquisition by Andrew Astor of 1000 shares of Nephros at 6.96 subject to Rule 16b-3 | 02/18/2025 |
6 | Nephros Amends CFO Employment Terms for Strategic Growth - TipRanks | 03/04/2025 |
7 | Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results | 03/06/2025 |
8 | Acquisition by Gwydir Tom of 27613 shares of Nephros subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 3.6 M | |
| Other Cashflows From Financing Activities | -75 K | |
| Price Earnings Ratio | 162.99 | |
| Free Cash Flow | 752 K |
Nephros |
Nephros Relative Risk vs. Return Landscape
If you would invest 148.00 in Nephros on December 18, 2024 and sell it today you would earn a total of 13.00 from holding Nephros or generate 8.78% return on investment over 90 days. Nephros is currently generating 0.2083% in daily expected returns and assumes 3.6904% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Nephros, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nephros Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nephros' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nephros, and traders can use it to determine the average amount a Nephros' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0564
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NEPH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.69 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Nephros is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nephros by adding it to a well-diversified portfolio.
Nephros Fundamentals Growth
Nephros Stock prices reflect investors' perceptions of the future prospects and financial health of Nephros, and Nephros fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nephros Stock performance.
| Return On Equity | 0.0087 | ||||
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 14.84 M | ||||
| Shares Outstanding | 10.54 M | ||||
| Price To Earning | (4.51) X | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 1.21 X | ||||
| Revenue | 14.16 M | ||||
| Gross Profit | 8.72 M | ||||
| EBITDA | 193 K | ||||
| Net Income | (1.57 M) | ||||
| Cash And Equivalents | 4.18 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.27 X | ||||
| Book Value Per Share | 0.81 X | ||||
| Cash Flow From Operations | 827 K | ||||
| Earnings Per Share | 0.01 X | ||||
| Market Capitalization | 17.19 M | ||||
| Total Asset | 11.86 M | ||||
| Retained Earnings | (144.41 M) | ||||
| Working Capital | 6.29 M | ||||
| Current Asset | 1.53 M | ||||
| Current Liabilities | 684 K | ||||
About Nephros Performance
By evaluating Nephros' fundamental ratios, stakeholders can gain valuable insights into Nephros' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nephros has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nephros has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.14) | |
| Days Of Inventory On Hand | 177.74 | 312.59 | |
| Return On Capital Employed | (0.16) | (0.15) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Nephros performance evaluation
Checking the ongoing alerts about Nephros for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nephros help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nephros may become a speculative penny stock | |
| Nephros had very high historical volatility over the last 90 days | |
| Nephros has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 14.16 M. Net Loss for the year was (1.57 M) with profit before overhead, payroll, taxes, and interest of 8.72 M. | |
| Nephros has a poor financial position based on the latest SEC disclosures | |
| About 13.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results |
- Analyzing Nephros' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nephros' stock is overvalued or undervalued compared to its peers.
- Examining Nephros' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nephros' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nephros' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nephros' stock. These opinions can provide insight into Nephros' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |